IDH1 and glioma: Yang et al. further confirmed that mutant IDH1 enhances 24OHC production, which activates LXR and leads to the inhibition of GBM cholesterol uptake, and cellular cholesterol reduction activates the SREBP pathway, thus stimulating cholesterol de novo synthesis, which endowed IDH1-mutant glioma cells with sensitivity to statins 47.